Sangamo Therapeutics is preparing to launch a Phase 1/2 clinical study in the United Kingdom to explore the potential…
Articles by Alice Melao
Treatment of atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab) should be maintained even after clinical deterioration, a case…
Clinical features and outcomes of patients with anti-factor H antibody, associated with atypical hemolytic uremic syndrome (aHUS), were reported in…
Treatment with Soliris (eculizumab, sold by Alexion) for recurrent atypical hemolytic uremic syndrome (aHUS) can result in the…
A novel genetic variant of the CFH gene, which encodes an important protein from the immune complement system,…
A rare case of atypical hemolytic uremic syndrome (aHUS) manifesting in generalized seizures in a 14-month-old girl highlights the importance…
Omeros Corporation’s lead therapy candidate, OMS721, being developed for the treatment of complement- and inflammation-related disorders including atypical…
Interval treatment with Soliris (eculizumab) may have a steady and prolonged effect in treating people with atypical hemolytic…
Treatment with Soliris (eculizumab) is an effective strategy to manage atypical hemolytic uremic syndrome (aHUS) even when manifested…
Omeros Corporation, in collaboration with the University of Cambridge, has established a new research center that will focus…